As part of our coverage from the 2016 American Society of Clinical Oncology annual meeting, experts Dr. Srdan Verstovsek, Dr. Elias Jabbour, Dr. Brady Stein and patient advocate, Andi Malitz, gathered to discuss the latest news and research in myeloproliferative neoplasms (MPNs). The experts reviewed promising results of recent studies, including telomerase inhibitors, antifibrotic treatments, the long-term benefit of the JAK inhibitor, ruxolitinib, as well as news about the promise of early intervention. Also discussed were observational studies and how these studies are providing experts with better understanding of the disease. The experts stressed the importance of balancing treatment choices with management of quality of life for patients. Listen to this discussion for a hopeful look at the future of MPN treatment and developing research.